Antibody-drug conjugate (ADC) specialist Seagen has claimed its ... as a second-line monotherapy for recurrent or metastatic cervical cancer. The accelerated approval for Tivdak (tisotumab vedotin ...

Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or following ...

The drug has been specifically authorised to treat adults experiencing disease progression on or after systemic therapy, and is now the first antibody-drug conjugate (ADC) to be approved in the EU for ...

"Recurrent or metastatic cervical cancer is a devastating disease ... that the anticancer activity of tisotumab vedotin is due to the binding of the ADC to TF-expressing cancer cells, followed by ...